RAMUCIRUMAB + PACLITAXEL:

THE FIRST AND ONLY FDA-APPROVED combination regimen included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with a CATEGORY 1 recommendation for the treatment of locally advanced or metastatic gastric or GEJ adenocarcinoma in the second-line setting1-3



A PREFERRED SECOND-LINE THERAPY OPTION2,3

CATEGORY 1 NCCN Guidelines® Recommendation:

CATEGORY 1: Based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.

*NCCN Guidelines for Gastric Cancer V.3.2016 recommend single-agent ramucirumab (CYRAMZA) and ramucirumab (CYRAMZA) in combination with paclitaxel as preferred second-line treatment options for advanced or metastatic gastric adenocarcinoma.


NCCN Guidelines for Esophageal and Esophagogastric Junction (EGJ) Cancers V.2.2016 recommend single-agent ramucirumab (CYRAMZA) and ramucirumab (CYRAMZA) in combination with paclitaxel as preferred second-line treatment options for EGJ adenocarcinoma.

CYRAMZA + PACLITAXEL: EFFICACY OVERVIEW1

Efficacy Overview

OS=overall survival; PFS=progression-free survival; ORR=objective response rate; CI=confidence interval.

The percentage of deaths at the time of analysis was 78% (256 patients) and 78% (260 patients) in the CYRAMZA plus paclitaxel and placebo plus paclitaxel treatment arms, respectively.
§Months=median months.
||The percentage of events at the time of analysis was 85% (279 patients) and 88% (296 patients) in the CYRAMZA plus paclitaxel and placebo plus paclitaxel treatment arms, respectively.
ORR=complete + partial response. Intent-to-treat (ITT) population. Disease progression and tumor response were assessed by investigators in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.4


References: 1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd. 2. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.3.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9, 2016. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc. 3. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed August 9, 2016. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc. 4. Wilke H, Muro K, Van Cutsem E, et al; for the RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.

Top